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Glucose transporter-1 deficiency syndrome is caused by mutations in the SLC2A1 gene in the majority of patients and results in
impaired glucose transport into the brain. From 2004–2008, 132 requests for mutational analysis of the SLC2A1 gene were
studied by automated Sanger sequencing and multiplex ligation-dependent probe amplification. Mutations in the SLC2A1 gene
were detected in 54 patients (41%) and subsequently in three clinically affected family members. In these 57 patients we
identified 49 different mutations, including six multiple exon deletions, six known mutations and 37 novel mutations (13
missense, five nonsense, 13 frame shift, four splice site and two translation initiation mutations). Clinical data were retro-
spectively collected from referring physicians by means of a questionnaire. Three different phenotypes were recognized: (i) the
classical phenotype (84%), subdivided into early-onset (52 years) (65%) and late-onset (18%); (ii) a non-classical phenotype,
with mental retardation and movement disorder, without epilepsy (15%); and (iii) one adult case of glucose transporter-1
deficiency syndrome with minimal symptoms. Recognizing glucose transporter-1 deficiency syndrome is important, since a
ketogenic diet was effective in most of the patients with epilepsy (86%) and also reduced movement disorders in 48% of
the patients with a classical phenotype and 71% of the patients with a non-classical phenotype. The average delay in diagnos-
ing classical glucose transporter-1 deficiency syndrome was 6.6 years (range 1 month–16 years). Cerebrospinal fluid glucose
was below 2.5mmol/l (range 0.9–2.4mmol/l) in all patients and cerebrospinal fluid : blood glucose ratio was below 0.50 in all
but one patient (range 0.19–0.52). Cerebrospinal fluid lactate was low to normal in all patients. Our relatively large series of 57
patients with glucose transporter-1 deficiency syndrome allowed us to identify correlations between genotype, phenotype and
biochemical data. Type of mutation was related to the severity of mental retardation and the presence of complex movement
disorders. Cerebrospinal fluid : blood glucose ratio was related to type of mutation and phenotype. In conclusion, a substantial
number of the patients with glucose transporter-1 deficiency syndrome do not have epilepsy. Our study demonstrates that a
lumbar puncture provides the diagnostic clue to glucose transporter-1 deficiency syndrome and can thereby dramatically reduce
diagnostic delay to allow early start of the ketogenic diet.
Keywords: GLUT1 deficiency syndrome; SLC2A1 gene; phenotype; cerebrospinal fluid; ketogenic diet
Abbreviations: GLUT1 = glucose transporter-1
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Introduction
Glucose transporter-1 (GLUT1) deficiency syndrome (OMIM
#606777) is an autosomal dominant haplo-insufficiency disorder,
leading to a reduced glucose transport into the brain (Seidner
et al., 1998). GLUT1 is highly expressed in the endothelial cells
of erythrocytes and the blood-brain barrier and is exclusively
responsible for glucose transport into the brain (Vannucci et al.,
1997; Barros et al., 2007). GLUT1 deficiency syndrome was first
described in 1991 by De Vivo et al. (1991). The classic patient
with GLUT1 deficiency syndrome presents with infantile
drug-resistant seizures, mild to severe developmental delay and
an acquired microcephaly in up to 50% of the cases. Hypotonia,
spasticity, ataxia and dystonia are elements of a complex move-
ment disorder (Klepper and Leiendecker, 2007). In recent years,
however, is has become apparent that the clinical spectrum of
GLUT1 deficiency syndrome is much broader (Brockmann,
2009). Patients with a non-classical phenotype featuring develop-
mental delay and movement disorders without epilepsy have been
described (Overweg-Plandsoen et al., 2003; Hennecke et al.,
2005; Friedman et al., 2006; Klepper et al., 2007), as well as
familial and sporadic paroxysmal exercise induced dyskinesia
with or without epilepsy (Suls et al., 2008; Weber et al., 2008;
Schneider et al., 2009).
When GLUT1 deficiency syndrome is suspected on clinical
grounds, a lumbar puncture in the fasting state should be per-
formed. GLUT1 deficiency syndrome is characterized by a low
glucose concentration in the cerebrospinal fluid (hypoglycorrha-
chia) in the absence of hypoglycaemia, in combination with a
low to normal lactate in the cerebrospinal fluid (Klepper et al.,
1999b; Klepper and Voit, 2002). It is important to recognize
GLUT1 deficiency syndrome, since the disorder can be treated
with a ketogenic diet. Ketone bodies use another transporter to
enter the central nervous system and thus can supply the brain
with an alternative fuel.
In most patients the ketogenic diet markedly reduces the fre-
quency of seizures (Klepper et al., 2005) and the severity of the
movement disorder (Brockmann, 2009). Behaviour and alertness
also frequently improve (Klepper et al., 2005, 2007; Joshi et al.,
2008).
For the diagnosis of GLUT1 deficiency syndrome, GLUT1 west-
ern blot analysis in erythrocyte membranes and glucose uptake
into erythrocytes can be applied to determine GLUT1 function.
Negative western blots or erythrocyte uptake studies, however,
do not rule out the diagnosis (Klepper et al., 1999a). GLUT1 defi-
ciency syndrome can be confirmed by mutation analysis of the
SLC2A1 gene. The SLC2A1 gene, mapped to the short arm of
chromosome 1 (1p35-31.3) (Shows et al., 1987), is a relatively
small gene and consists of ten exons, spanning 2842 base pairs
encoding 493 amino acids (Fukumoto et al., 1988).
The structure and function of the GLUT1 protein has been
intensively investigated (Hruz and Mueckler, 2001). The
amino-acid sequence of the GLUT1 protein is highly conserved,
with 97–98% identity between the human, rat, rabbit, mouse
and pig sequences, which implies that all domains of this protein
are functionally important (Baldwin, 1993). GLUT1 has
12 transmembrane alpha-helices (Mueckler et al., 1985), separated
by a large intracellular loop between helices 6 and 7. A 3D model
for GLUT1 has been proposed, predicting a central aqueous
channel communicating the extracellular and intracellular compart-
ments, with many residues crucial for glucose transport located
around this central channel (Mueckler and Makepeace, 2009).
Since the first description of GLUT1 deficiency syndrome and
the elucidation of its genetic cause, a wide spectrum of around 60
different mutations in the SLC2A1 gene has been described in
approximately 100 patients (Wang et al., 2005; Klepper and
Leiendecker, 2007), including large-scale deletions, missense, non-
sense, frame shift and splice-site mutations. All mutations either
lead to absence or loss of function of one of the SLC2A1 alleles.
Several hot spots for recurrent mutations have been identified
(Asn34, Gly91, Ser113, Arg126, Arg153, Arg264, Thr295,
Arg333) (Klepper and Leiendecker, 2007). Thus far, correlations
between phenotype and genotype remained elusive (Wang et al.,
2005; Brockmann, 2009). Here we report on the genetic, bio-
chemical and clinical characteristics of 57 newly diagnosed patients
with GLUT1 deficiency syndrome.
Materials and methods
Patients
From January 2004 to July 2008 the DNA Diagnostics Laboratory
(Department of Human Genetics of the Radboud University
Nijmegen Medical Centre, The Netherlands) received 132 requests
for mutational analysis of the SLC2A1 gene in patients suspected to
have GLUT1 deficiency syndrome from all over the world (excluding
the requests for carrier testing in parents and other family members of
affected patients). In 54 patients (41%) suspicion of GLUT1 deficiency
syndrome was confirmed by the identification of a pathogenic muta-
tion in the SLC2A1 gene. Additionally, we identified a mutation in the
SLC2A1 gene in three clinically affected family members, bringing the
total number of patients with GLUT1 deficiency syndrome confirmed
by mutation analysis to 57. Clinical data were retrospectively collected
from referring physicians by means of a written, detailed question-
naire. Results were reviewed against the background of the existing
literature on SLC2A1 gene mutations and associated phenotypes.
Mutation analysis
Genomic DNA was extracted from blood samples by standard proce-
dures. Automated Sanger sequencing was performed to study the
entire coding sequence including at least 20 base pairs of intronic
sequence flanking each exon of the SLC2A1 gene. Polymerase chain
reaction (PCR) amplification of all 10 exons of the SLC2A1 gene was
performed using Fast PCR Master Mix (Applied Biosystems, Foster
City, California, USA). Primer sequences are available upon request.
Sequencing reactions were carried out using BigDye V. 3.1 (Applied
Biosystems) and analysed on an ABI 3730 capillary sequencer (Applied
Biosystems). Sequences were compared to the wild-type sequence as
submitted to Genbank (Genbank Accession Number NM_006516). All
previously unreported mutations were verified in a panel of at least
100 control alleles. The reference sequence was used in which the A of
the ATG start-codon is designated position 1. Amino-acid residues
were numbered from the first methionine residue; according to the
protein accession number NP_006507.
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Single or multiple exon deletions or duplications of the SLC2A1 gene
using multiplex ligation-dependent probe amplification were analysed
in all patients. Multiplex ligation-dependent probe amplification is a
technique for measuring allele dosage and identifies the target
sequence by hybridization of two adjacent complementary probes
(Schouten et al., 2002). Multiplex ligation-dependent probe amplifica-
tion was carried out using the SALSA MLPA kit P138 SLC2A1 (MRC
Holland, Amsterdam, The Netherlands) according to the manufac-
turer’s instructions. A visual comparison of the peak profiles was
made to identify copy number changes. Heterozygous deletions of
probe recognition sequences should give 35–50% reduced relative
peak area of the amplification product of that probe.
Statistical analysis
Statistical analyses were performed using Statistical Package for the
Social Sciences version 16.0 (SPSS INC, Chicago, IL, USA). Mean dif-
ferences in CSF parameters between patients with a different geno-
type or phenotype were assessed by means of analysis of variance
(one-way ANOVA) using planned contrasts for group comparisons.
Correlation between phenotype and genotype was tested using the
Pearson Chi square test (two-sided testing for a significance level of
P4 0.05).
Results
Molecular data
Out of 57 patients, 6 (11%) were identified with a multiple exon
deletion of the SLC2A1 gene detected by multiplex
ligation-dependent probe amplification. In 51 patients a patho-
genic mutation in the SLC2A1 gene was identified by DNA
sequence analysis (Table 1). We identified 37 different novel
pathogenic mutations, including 13 missense, 5 nonsense,
13 frame shift, 4 splice and 2 translation initiation mutations. We
identified two different de novo mutations in amino-acid residue
1 (c.1A4G and c.3G4A). Since the mutations were located in the
transcription codon of the SLC2A1 gene, transcription was not
initiated, which is consistent with haplo-insufficiency. We identi-
fied 17 different missense mutations in the SLC2A1 gene, 13 of
which were novel. Eleven novel missense mutations were
identified in patients with the classical phenotype of GLUT1 defi-
ciency syndrome of epilepsy and mental retardation in combination
with movement disorders (p.Asn34Tyr, p.Met96Val, p.Ala155Val,
p.Arg212Cis, p.Arg212His, p.Arg223Trp, p.Glu329Gln,
p.Arg333Gln, p.Gly382Asp, p.Ala405Asp, p.Pro485Leu). The
novel missense mutation p.Arg153His was identified in Patient 48
with the non-classical phenotype of mild mental retardation with
continuous ataxia and paroxysmal dystonia and choreoathetosis.
CSF in this patient showed a characteristic pattern of low CSF glu-
cose (1.8 mmol/l) in combination with low CSF : blood glucose ratio
(0.38) and low CSF lactate (1.0 mmol/l). The novel missense muta-
tion p.Val303Leu was identified in Patient 57. This patient was lost
as follow-up and clinical data were unavailable. DNA of the parents
of this patient was not investigated.
All previously unreported mutations were verified in a panel of
at least 100 control alleles. Mutations were not mentioned
as non-pathogenic polymorphism in the Single Nucleotide
Polymorphism database. Two mutation prediction programs were
used to predict the pathogenicity of mutations [PolyPhen
(Polymorphism Phenotyping) and SIFT (Sorting Intolerant from
Tolerant)]. The mutations that we identified and all mutations in
the SLC2A1 gene that have been described previously are repre-
sented in Fig. 1 (Klepper et al., 2007; Klepper and Leiendecker,
2007; Ito et al., 2008; Joshi et al., 2008; Roulet-Perez et al., 2008;
Suls et al., 2008; Takahashi et al., 2008; Ticus et al., 2008; Weber
et al., 2008; Zorzi et al., 2008; Bertsche et al., 2009; Slaughter
et al., 2009).
Autosomal dominant transmission
We identified four families with autosomal dominant transmission
of GLUT1 deficiency syndrome. Patient 11 (Table 2), the mother
of Patient 49 (Table 4) was diagnosed with GLUT1 deficiency
syndrome after diagnosis was made in her daughter. Whereas
her daughter had a non-classical phenotype, with mild mental
retardation with continuous ataxia with paroxysmal worsening,
the mother had the early-onset classical phenotype of epilepsy
with mild mental retardation and paroxysmal ataxia.
Patient 55, the mother of Patient 23 (Table 2), was diagnosed
with GLUT1 deficiency syndrome after diagnosis was made in her
son. The son had the early-onset classical phenotype with a mild
mental retardation without movement disorders, whereas the
mother had a minimal phenotype with a normal psychomotor
development and ‘clumsiness’ after prolonged fasting.
The missense mutation Arg93Trp was also identified in the
brother and mother of Patient 50 (Table 4). Patient 50 had a
non-classical phenotype of severe mental retardation with
chorea. The brother had epilepsy and a mild mental retardation.
The mother had epilepsy and a normal intelligence within the
lower range (based on the clinical impression of the treating
physician).
In one other family the mutation in the SLC2A1 gene was most
likely transmitted in an autosomal dominant way. A mutation in
the SLC2A1 gene was identified in Patient 45 (Table 3) after diag-
nosis of GLUT1 deficiency syndrome was made in his brother
(Patient 15, Table 2). Patient 15 had the early-onset classical phe-
notype with severe mental retardation, whereas Patient 45 had
the late-onset classical phenotype with only mild mental retarda-
tion. DNA of their mother was investigated and did not show the
mutation. Clinical data and DNA of the father were unavailable.
In all other cases where both parents had been tested (n= 11;
22%) the mutation had occurred as a de novo event.
Biochemical characteristics
The biochemical characteristics of the patients are listed in
Tables 2—4. All patients had low CSF glucose concentrations
(52.5 mmol/l). The CSF glucose values (reference range 2.5–
3.7 mmol/l) were 0.9–2.4 mmol/l (mean 1.8 mmol/l; SD 0.3).
CSF : blood glucose ratios (reference range 0.5–0.8) ranged from
0.19 to 0.52 (mean 0.37; SD 0.07). CSF lactate (reference range
1.3–1.9 mmol/l) ranged from 0.6 to 1.5 mmol/l (mean 1.0 mmol/l;
SD 0.2), with a CSF lactate below 1.3 mmol/l in 78% of the
patients.
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Clinical characteristics
We obtained clinical data of 55 patients (96%). The clinical char-
acteristics are listed in Tables 2–4. Two patients (56 and 57) were
lost to follow-up and clinical data were unavailable. We recog-
nized three different phenotypes. The most frequent, ‘classical’
phenotype (n= 46; 84%) represented patients with refractory epi-
lepsy and developmental delay. Patients generally had an onset of
Table 1 Mutations in the SLC2A1 gene in 51 novel GLUT1 deficiency syndrome patients
Exon Nucleotide Amino
acid
Location Type of
mutation
Patient
number
Phenotype Referencesa
1 c.1A4G p.Met1? Transcription codon B 42 B –
1 c.3G4A p.Met1? Transcription codon B 26 A –
Intron 1 c.18 + 1G4C – – B 24 A –
Intron 1 c.18 + 1G4A – – B 23, 55 A, minimal Wang et al., 2000
2 c.32_33del – Helix 1 B 21 A –
2 c.100A4T p.Asn34Tyr Extracellular loop 1–2 A 1 A –
Intron 2 c.115-1G4A – – B 17 A –
3 c.124G4T p.Glu42X Extracellular loop 1–2 B 46 B –
3 c.160G4T p.Glu54X Extracellular loop 1–2 B 54 C –
3 c.170dup – Extracellular loop 1–2 B 18 A –
4 c.277C4T p.Arg93Trp Cytoplasmic loop 2–3 A 50 C Joshi et al., 2008
4 c.286A4G p.Met96Val Helix 3 A 3 A –
4 c.305_308del – Helix 3 B 43 B –
4 c.338_352delinsTTGAG – Helix 3 B 13 A –
4 c.354_355insT – Extracellular loop 3–4 B 14 A –
4 c.376C4T p.Arg126Cys Helix 4 A 6, 11, 47, 49 A, A, C, C Pascual et al., 2002;
Zorzi et al., 2008
4 c.388G4A p.Gly130Ser Helix 4 A 5 A Wang et al., 2005
4 c.458G4A p.Arg153His Cytoplasmic loop 4–5 A 48 C –
4 c.464C4T p.Ala155Val Helix 5 A 39, 37 B, B –
4 c.481C4T p.Gln161X Helix 5 B 28 A –
4 c.505_507del – Helix 5 B 20 A Pascual et al.2002;
Wang et al., 2005
5 c.634C4T p.Arg212Cys Cytoplasmic loop 6–7 A 8 A –
5 c.635G4A p.Arg212His Cytoplasmic loop 6–7 A 7 A –
5 c.667C4T p.Arg223Trp Cytoplasmic loop 6–7 A 40 B –
6 c.715_716insC – Cytoplasmic loop 6–7 B 25 A –
6 c.727G4T p.Glu243X Cytoplasmic loop 6–7 B 16 A –
6 c.737_741del – Cytoplasmic loop 6–7 B 56 NA –
6 c.746del; 746-747ins9 – Cytoplasmic loop 6–7 B 15, 45 A, B –
6 c.790dup – Cytoplasmic loop 6–7 B 19 A –
6 c.798_799insC – Cytoplasmic loop 6–7 B 12 A –
6 c.844C4T p.Gln282X Helix 7 B 29 A –
Intron 6 c.864-1G4C – – B 52 C –
7 c.884C4T p.Thr295Met Extracellular loop 7–8 A 9 A Wang et al., 2005;
Fuji et al., 2008
7 c.907G4T p.Val303Leu Extracellular loop 7–8 A 57 NA –
7 c.966_971delinsT – Helix 8 B 51 C –
8 c.985G4C p.Glu329Gln Cytoplasmic loop 8–9 A 4 A –
8 c.988C4T p.Arg330X Cytoplasmic loop 8–9 B 30, 44 A, B Wang et al., 2000;
Ito et al., 2008
8 c.998G4A p.Arg333Gln Cytoplasmic loop 8–9 A 38 B –
9 c.1100dup – Extracellular loop 9–10 B 53 C –
9 c.1145G4A p.Gly382Asp Helix 10 A 2 A –
9 c.1214C4A p.Ala405Asp Helix 11 A 41 B –
Intron 9 c.1279-1G4C – – B 22 A –
10 c.1346_1359del – Helix 12 B 27 A –
10 c.1454C4T p.Pro485Leu Cytoplasmic tail A 10 A –
Type of mutation: A = missense mutation, B = nonsense, frame shift, splice site, or translation initiation mutation. Six patients with a multiple exon deletion of the SLC2A1
gene (deletion of exon 2–10 in Patient 34 and deletion of exon 1–10 in Patients 31, 32, 33, 35 and 36) are not represented in the table. Phenotype: A = early-onset classical
phenotype; B = late-onset classical phenotype; C = non-classical phenotype; NA = data not available.
a: Patients with the same mutation described previously in the literature.
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Missense/nonsense Deletions, insertions, frame shift, splice site
p.Arg223Trp*
p.Arg218His
p.Arg212His (2)**
(Roulet-Perez et al., 2008)
p.Arg212Cys*
p.Asn317Thr (Suls et al., 2008)
p.Gly314Ser(6) (Weber et al., 2008)
p.Thr310Ile
p.Val303Leu*
p.Thr295Met (3)***
p.Arg333Gln*
p.Arg333Trp (4) 
(Takahashi et al., 2008)
p.Arg330X (4)*** (Ito et al., 2008)
p.Glu329Gln*
p.Pro485Leu**
(Slaughter et al., 2009)
p.Lys456X
p.Tyr449X
227
114
115
972
1074
1075
c.227_228insG
c.189_190ins23
c.170dup*
c.680-1G>C
c.678T>G; 679G>A; 679+1del
c.654dup (Suls et al., 2008)
c.966_971delinsT*
c.970del
c.907del
c.864-1G>C*
493
172
173
91
92
38
39
6
7 19
18 
275
276
516
517
679
324
325
358
359
426
427
288
289
228 680
863
864
973
1278
1279
c.1383_1384ATCG
c.1377dup (Bertsche et al., 2009)
c.1348_1361dupTTCAAAGTTCCTG
c.1346_1359del*
c.1216_1220delGTTGC
c.1198delC
c.1185delC
c.1100dup**
p.Gln283X (Zorzi et al., 2008)
p.Gln282X*
p.Ala275Thr (4) (Weber et al., 2008)
p.Lys256Val 
p.Glu243X*
p.Gln161X*
p.Ala155Val (2)*
p.Arg153Leu (2)
p.Arg153Cys
p.Arg153His*
p.Glu146Lys
p.Val140Met (Suls et al., 2008)
p.Cys133X
p.Gly130Ser (2)***
p.Arg126Cys (7)***
(Zorzi et al., 2008)
p.Arg126His (4)
p.Arg126Leu
p.Met96Val*
p.Ser95Ile (22) (Suls et al., 2008)
p.Arg93Trp(2)***(Joshi et al., 2008)
 9
 6
 5
 3
 2
 1
p.Asn34Ile
p.Asn34Ser(2)
p.Asn34Tyr*
p.Tyr28X
p.M1Ile*
p.M1Val*
c.980_981delTG
c.855_856ins12
c.843_854del (4) (Weber et al., 2008)
c.798_799insC*
c.790del; 792C>T
c.790del
c.790dup**
c.746del; 746_747ins9*
c.745_746insC
c.737_741del*
c.725del
c.715_716insC*
c.709_710insG
c.683del
c.562_563insC
c.507_508dup
c.505_507del (3)***
c.371_381dup
c.354_355insT
c.338_352delinsTTGAG*
c.337_338insTTGAG; c.338_352del (2)
c.337_381dup
c.305_308del*
c.81_92dup
c.87delC; 88A>T
c.32_33del*
c.18+1G>A(2)***
c.18+1G>C*
c.972+981G>T
c.115-1G>A*
c.1279-1G>C** (Ticus et al., 2008)
Amino-acid Nucleotide
p.Ala405Asp*
p.Gln397X
p.Gly382Asp*
 7
p.Gly91Asp (3)
p.Gly75Trp
p.Ser66Phe
p.Glu54X*(Klepper et al., 2007)
p.Trp48X (Zorzi et al., 2008)
p.Glu42X*
10
 8
 4
Figure 1 Distribution of 100 different pathogenic mutations in the SLC2A1 gene in 162 patients with GLUT1 deficiency syndrome that
were identified by us or have previously been described in literature. Six patients that we identified with a heterozygous multiple exon
deletion and five patients that were described previously with haplo-insufficiency of the SLC2A1 gene are not represented. The black
vertical line represents the GLUT1 gene with boxes indicating the exons. The left hand diagram shows missense and nonsense mutations.
Amino-acid residues at the intron/exon boundaries are shown. The right hand diagram shows frame shift and splice-site mutations.
Nucleotides at the intron–exon boundaries are indicated. Genbank Accession Number NM_006516 was used as the SLC2A1 reference
sequence in which the A of the ATG start-codon is designated position 1. Some mutations have been reported in the past with a different
reference sequence (in which the A of the ATG start-codon is +180); we have adapted these mutations to the reference sequence as
mentioned above. The number between brackets represents total number of patients identified with the mutation. Mutation hot spots are
represented in bold. Novel mutation identified in our patient group. Novel mutation identified in one of our patients that has previously
been reported as a case report. Mutation identified in our patient group that has previously been reported in other patients. References
of mutations that have been described by others after 2007 are mentioned. All other mutations have been described previously by Klepper
and Leiendecker (2007).
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seizures before the age of 2 years (early-onset classical phenotype,
n= 36 (65%; Table 2), however we also encountered patients with
the onset of seizures later in life (late-onset classical phenotype,
n= 10 (18%; Table 3). Seizure semiology was diverse. In the first
year of life paroxysmal eye movements, cyanotic spells, complex
absences and atonic seizures were observed. In later years, myo-
clonic seizures and generalized tonic–clonic attacks were seen.
Seizure frequency varied from daily to sporadic attacks. Mental
retardation ranged from mild (n= 13; 36%) to moderate (n= 16;
44%) or severe (n= 6; 17%) in patients with the early-onset clas-
sical phenotype (data on the severity of mental retardation of one
patient were unavailable). In patients with the late-onset classical
phenotype severity of mental retardation ranged from mild (n= 7;
70%) to moderate (n= 3; 30%). Complex movement disorders
(ataxia, dystonia or chorea) were seen in 69% (n= 25) of the
patients with the early-onset and in 90% (n= 9) of patients with
the late-onset classical phenotype. Movement disorders were
either continuous, paroxysmal or continuous with paroxysmal wor-
sening. Data on head growth were available in 39 patients (85%)
with the classical phenotype. Microcephaly was seen in 14 out of
32 patients (44%) with the early-onset, and in two out of seven
patients (29%) of the patients with the late-onset classical
phenotype.
Furthermore, we observed a non-classical phenotype of patients
with a mental retardation and movement disorder, but without
epilepsy (n= 8; 15%; Table 4). Mental retardation ranged from
mild (n= 4; 50%) to moderate (n= 2; 25%) or severe (n= 2;
25%). Ataxia was seen in 75% (n= 6), dystonia in 50% (n= 4),
and chorea in 38% (n= 3) of the patients with this non-classical
phenotype. Movement disorders were continuous, paroxysmal, or
continuous with paroxysmal worsening. Paroxysmal movement
disorders were mostly triggered by fasting or exercise.
Microcephaly was seen in 50% (n= 4) of the patients with the
non-classical phenotype.
Finally, we identified one adult case of GLUT1 deficiency syn-
drome (Patient 55, the mother of Patient 24) with a normal psy-
chomotor development and only minimal symptoms. She had one
seizure when she was 2-years-old and is ‘clumsy’ after prolonged
fasting.
Response to the ketogenic diet
A ketogenic diet was started in 37 out of 46 patients (80%) with
the classical phenotype. Out of these 37 patients, 24 (62%)
became totally seizure free after introduction of the diet and sei-
zure reduction was seen in nine patients (24%). The frequency
and/or severity of movement disorders was significantly reduced
in 12 out of 29 patients (41%) with the classical phenotype in
combination with a movement disorder. In two patients (7%) the
movement disorder totally disappeared after introduction of the
ketogenic diet. One of these patients (38) had paroxysmal
ataxia. The other patient (33) had paroxysmal ataxia and dystonia.
The diet, however, was stopped in Patient 33 because of incom-
pliance. The diet was also stopped in two other patients with the
classical phenotype, due to non-compliance.
The ketogenic diet was started in seven out of eight patients
(88%) with a non-classical phenotype. Reduction of the frequency
and/or severity of the movement disorder was seen in five out of
seven patients (71%). The diet was stopped with one patient due
to incompliance.
Subjective improvement of cognitive function after initiation of
the ketogenic diet was seen in 19 out of 37 patients (51%) with a
classical phenotype and in two out of seven patients (29%) with
the non-classical phenotype.
Relation between genotype and
phenotype
We identified specific relations between genotype and phenotype.
First, type of mutation was correlated with the severity of mental
retardation. Mild mental retardation was seen in 79% (n= 15) of
the patients with a missense mutation (‘type A mutation’; Table 2–
4), whereas only 26% (n= 9) of the patients with a nonsense,
frame shift, splice site, or translation initiation mutation (‘type B
mutation’), or multiple exon deletion (‘type C mutation’) had mild
mental retardation (P= 0.000). Second, type of mutation was cor-
related with the presence of movement disorders. Movement dis-
orders were less frequently seen in patients with type A mutations
(63%; n= 12) than in patients with type B or C mutations (88%;
n= 30; P= 0.037). Third, all six patients with type C mutations had
the early-onset classical phenotype, whereas 38% (n= 18) of the
patients with type B mutations had the late-onset or non-classical
phenotype (P= 0.075). The non-classical phenotype was seen in
both patients with type A (20%; n= 4) and patients with type B
mutations (14%; n= 4). Patients with identical mutations were
heterogeneous in phenotype and severity of mental retardation.
Relation between genotype and
biochemical data
The CSF : blood glucose ratio was lower in patients with type C
(0.32; SD 0.07) than in patients with type A mutations (0.40; SD
0.06; P= 0.009) (Fig. 2). Patients with type B mutations also had a
lower CSF : blood glucose ratio (0.35; SD 0.06) than patients with
type A mutations (0.40; SD 0.06; P= 0.013). The CSF : blood glu-
cose ratio did not differ significantly between patients with type B
or type C mutations (P= 0.289). The CSF glucose value was lower
in patients with type C (1.48 mmol/l; SD 0.34) than in patients
with type A mutations (1.96 mmol/l; SD 0.26; P= 0.001). The CSF
glucose value was also lower in patients with type B (1.68 mmol/l;
SD 0.30) than in patients with type A mutations (1.96 mmol/l; SD
0.26; P= 0.003). The CSF glucose did not differ significantly
between patients with type B or type C mutations (P= 0.150).
CSF lactate did not differ significantly between patients with the
type A (1.10 mmol/l; SD 0.23), type B (0.97 mmol/l; SD 0.23), or
type C mutations (1.20 mmol/l; SD 0.35; P= 0.129).
Relation between phenotype and bio-
chemical data
Patients with the early-onset classical phenotype had a lower
CSF : blood glucose ratio (0.35; SD 0.07) than patients with the
late-onset classical phenotype (0.41; SD 0.07; P= 0.009) and
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patients with the non-classical phenotype (0.41; SD 0.044;
P= 0.005) (Fig. 2). The CSF glucose value did not differ signifi-
cantly between patients with the early-onset classical (1.7 mmol/l;
SD 0.35), late-onset classical (1.9 mmol/l; SD 0.30), or
non-classical phenotype (1.8 mmol/l; SD 0.19; P= 0.145). CSF lac-
tate did not differ significantly between patients with the
early-onset classical (1.03 mmol/l; SD 0.27), late-onset classical
(1.16 mmol/l; SD 0.18), or non-classical phenotype (0.94 mmol/l;
SD; 0.15; P= 0.264).
Discussion
Our data confirm the wide clinical spectrum of GLUT1 deficiency
syndrome as recently described (Brockmann, 2009). The absence
of epilepsy in patients with GLUT1 deficiency syndrome is consid-
ered uncommon and has only been described in a small number of
patients (Overweg-Plandsoen et al., 2003; Hennecke et al., 2005;
Friedman et al., 2006; Klepper et al., 2007). We have, however,
identified a relatively large number of patients in our cohort (n= 8;
15%) with the non-classical phenotype of mental retardation and
movement disorders without epilepsy. Another non-classical phe-
notype of paroxysmal exercise-induced dyskinesia was recently
described (Suls et al., 2008; Weber et al., 2008; Schneider et
al., 2009). We did not identify patients with the latter phenotype
in our study cohort, but we expect that with the increasing aware-
ness of the clinical variety of GLUT1 deficiency syndrome, diag-
nosis will be made more frequently in patients with a non-classical
phenotype.
Recognizing GLUT1 deficiency syndrome is important since it
can be treated with a ketogenic diet. The ketogenic diet is a
high-fat, low carbohydrate, normocaloric diet which results in per-
manent ketosis and provides the brain with an alternative fuel
(Klepper et al., 2004). It is currently believed that the ketogenic
diet should be initiated as soon as possible and should be main-
tained at least until adolescence (Klepper et al., 2005; Brockmann,
2009). In our study cohort, the ketogenic diet was effective in
most of the patients with epilepsy (86%) and also reduced move-
ment disorders significantly in 48% of the patients with the clas-
sical phenotype and 71% of the patients with a non-classical
phenotype. Effectiveness of the ketogenic diet in a series of
drug-resistant epileptic patients with GLUT1 deficiency syndrome
has previously been described (Klepper et al., 2005), but improve-
ment of movement disorders in patients with a non-classical phe-
notype has only been observed in case reports (Friedman et al.,
2006; Brockmann, 2009). Our study underlines the importance of
initiating a ketogenic diet, not only in patients with epilepsy, but
also in patients with movement disorders without epilepsy.
Although subjective improvement of cognitive function, behaviour
and alertness was reported in a substantial number of our patients,
no objective data exist on the effect of the ketogenic diet on
cognitive function. Prospective follow-up studies with standardized
neurocognitive tests are needed.
The delay in diagnosing GLUT1 deficiency syndrome is consid-
erable. Patients with the classical phenotype were diagnosed at an
average of 6.6 years after the onset of seizures (range 1 month–
16 years) (Tables 2 and 3). Our study demonstrates that a lumbar
puncture provides the diagnostic clue to GLUT1 deficiency syn-
drome and can thereby dramatically reduce diagnostic delay to
allow early start of the ketogenic diet. All GLUT1 deficiency syn-
drome patients in our cohort had a low CSF glucose concentration
(52.5 mmol/l) and all but one patient had a low CSF : blood glu-
cose ratio (50.50). Differentiation with other causes of a low CSF
glucose and low CSF : blood glucose ratio (bacterial, fungal, or
protozoal meningitis and subarachnoidal haemorrhage) can be
made not only on the clinical symptoms or CSF cultures, but
also on CSF lactate concentrations. Neurons can use lactate as
an alternative fuel under circumstances of hypoglycaemia. A low
CSF lactate in most patients with GLUT1 deficiency syndrome is
therefore thought to reflect the glucose shortage in the brain
(Wang et al., 2006). CSF lactate was below 1.6 mmol/l in all
our patients and below 1.3 mmol/l in 78% of the patients,
whereas CSF lactate is elevated (42.0 mmol/l) in meningitis and
subarachnoidal haemorrhage (Cameron et al., 1993). Furthermore,
CSF cell count and protein are normal in GLUT1 deficiency syn-
drome. We therefore advise to perform a lumber puncture in
patients with drug-resistant epilepsy and mental retardation, as
well as in patients with unexplained movement disorders, espe-
cially if movement disorders worsen or occur after fasting or exer-
cise. Patients with paroxysmal exercise-induced dyskinesia due to
GLUT1 deficiency syndrome have been observed in the absence of
mental retardation, migraine or epilepsy (Schneider et al., 2009).
Notably, in patients with GLUT1 deficiency syndrome with this
non-classical phenotype of familial exercise-induced dyskinesia
the CSF is less sensitive for diagnosing GLUT1 deficiency
syndrome, as normal values for CSF : blood glucose ratio (0.47–
0.60; mean 0.52) and CSF glucose (1.8–3.6 mmol/l; mean
2.4 mmol/l) can be found (Suls et al., 2008).
Our results demonstrate that GLUT1 deficiency syndrome is
caused by (partial) deletion of the SLC2A1 gene in at least 10%
of the patients with GLUT1 deficiency syndrome confirmed by
DNA analysis. To date, only five GLUT1 deficiency syndrome
patients with a large scale deletion have been reported (De Vivo
et al., 1991; Seidner et al., 1998; Wang et al., 2000; Vermeer
et al., 2007). Perhaps, multiple exon deletions of a SLC2A1 allele
are under-diagnosed at the DNA level as a cause of GLUT1 defi-
ciency syndrome. We advise using multiplex ligation-dependent
probe amplification in every patient suspected of GLUT1 defi-
ciency syndrome, especially in patients with an early-onset classical
phenotype, since all patients identified with a multiple exon dele-
tion had this phenotype. By performing multiplex
ligation-dependent probe amplification in combination with
Sanger-based automated sequencing we were able to confirm sus-
picion of the clinical and/or biochemical diagnosis of GLUT1 defi-
ciency syndrome at the DNA level in 42% of all requests for DNA
analysis of the SLC2A1 gene. Regulatory sequences of the SLC2A1
gene, e.g. promoter sequences and/or sequences deep in introns
are not included in the molecular diagnostic strategy. Possible
mutations in these regions thus may not have been uncovered.
We identified 13 novel missense mutations in the SLC2A1 gene.
Eleven of these missense mutations were found in patients with
the classical phenotype of GLUT1 deficiency syndrome of epilepsy
and mental retardation in combination with movement disorders
and a characteristic CSF pattern, which would support the
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presence of a pathogenic GLUT1 allele. Since just a single DNA
variant was identified in the coding region in these cases, this
strongly suggests the potential pathogenic nature of these muta-
tions. Furthermore, the position of the mutations in the GLUT1
protein indicates the pathogenicity of the individual mutations. A
novel missense mutation was identified in exon 2 (p.Asn34Tyr).
Asn34 is the first amino acid in the large extracellular loop con-
necting transmembrane domains 1 and 2 (Hruz and Mueckler,
2001). It is a conserved residue in most of the GLUT subclasses
(Joost and Thorens, 2001) and therefore appears to be a crucial
residue for glucose transport. Three other patients have previously
been reported with a missense mutation at this location (Wang
et al., 2000; Overweg-Plandsoen et al., 2003; Klepper et al.,
2005). Two of our patients had the novel missense mutation
p.Ala155Val. Ala 155 is part of the transmembrane segment 5,
which is predicted to be part of the central channel of GLUT1 and
is therefore critical for glucose transport (Salas-Burgos et al.,
2004). The alanine residue is part of an evolutionary conserved
amino-acid stretch (in mouse, rat, dog, chicken, xenopus and
fugus). The novel missense mutations p.Arg212His and
p.Arg212Cys were identified in the Patients 7 and 8. Arg212 is
part of the large cytoplasmic loop between helices 6–7. Another
novel missense mutation was located in the cytoplasmic loop
between helices 6–7 (p.Arg223Trp). This mutation is considered
pathogenic, since it is not documented in the Single Nucleotide
Polymorphism database and has not been identified in more than
100 control alleles. The ‘Sorting Intolerant from Tolerant’ (SIFT)
program predicts that the protein will not tolerate the amino-acid
change. Several other crucial residues have previously been iden-
tified in this loop [Arg218 (Klepper et al., 2005), Lys256 (Wang
et al., 2000), Ala275 (Weber et al., 2008)]. We identified a novel
mutation in exon 8 (p.Glu329Gln). Glu329 is located at the cyto-
plasmic loop between helices 8–9. Mutation of Glu345 in the
cytoplasmic loop between helices 8–9 in GLUT4, which corre-
sponds with Glu329 in GLUT1, has been shown to lock the trans-
porter in an inward-facing confirmation (Schurmann et al., 1997).
Another novel missense mutation was found in exon 8
(Arg333Gln). Arg 333 is part of the highly conserved amino-acid
motif Arg-X-Gly-Arg-Arg between helix 8–9. The positive charges
in the motif form critical local cytoplasmic anchor points involved
in determining the membrane topology in GLUT1. These
Arg-X-Gly-Arg-Arg motifs are conserved in many of the members
of the major facilitator superfamily. Removal of the positive
charges in these motifs causes an aberrant flipping of the corre-
sponding cytoplasmic loop into the exoplasmic compartment (Sato
and Mueckler, 1999). Two novel missense mutations were
detected in exon 9 (p.Gly382Asp and p.Ala405Asp). Gly382 is
located in helix 10 and concerns an evolutionary high conserved
residue. Transmembrane segment 10 forms a part of the central
aqueous channel. Expression of a Gly382Asp mutant in X. laevis
oocytes showed abolished glucose transport capacity and reduced
GLUT1 expression on the cell membrane (Mueckler and
Makepeace, 2002). Ala405 is located in transmembrane segment
11, which is also predicted to be part of the central aqueous
channel. Cysteine-scanning mutagenesis of transmembrane seg-
ment 11 showed that Ala405 had significantly increased
specific activity relative to the cysteine-less protein (Hruz and
Mueckler, 2000). Cysteine and alanine are both amino acids
with non-polar side chains. Our patient, however, had alanine
replaced by aspartic acid, an amino acid with a polar side chain
and negative side chain charge, which changes the hydropathy
and therefore is likely to disrupt glucose transport across the aque-
ous central channel. A novel heterozygous mutation was detected
in Patient 10 in exon 10 (p.Pro485Leu). The mutation was located
in the cytoplasmic carboxyl tail of the GLUT1 protein and was
proven to be de novo.
We cannot completely prove the pathogenic nature of two
novel missense mutations. Missense mutation p.Arg153His was
identified in a patient with a non-classical phenotype of mild
mental retardation, continuous ataxia and paroxysmal dystonia
and choreoathetosis. The DNA of the parents of this patient was
not investigated. The characteristic CSF pattern with low CSF glu-
cose, low CSF : blood glucose ratio and low CSF lactate, however,
supports the pathogenicity of this mutation. Furthermore, Arg153
is positioned in the cytoplasmic loop between helix 3 and 4 and is
a crucial residue in a conserved domain. Arg153 is one of the
known mutation hotspots in GLUT1 deficiency syndrome
(Klepper and Leiendecker, 2007). Patient 57 was identified with
the novel missense mutation p.Val303Leu. Val303is located in the
exofacial loop between helix 7–8. This patient, unfortunately, was
lost to follow-up and clinical data were unavailable. The DNA of
the parents of the patient was not investigated. The pathogenic
nature of this mutation cannot, therefore, be supported.
Autosomal dominant transmission of GLUT1 deficiency syn-
drome has only been described in a few families with paroxysmal
exercise-induced dyskinesia (Suls et al., 2008; Weber et al., 2008)
and some families with the classical phenotype of GLUT1 defi-
ciency syndrome (Brockmann et al., 2001; Klepper et al., 2001).
We identified autosomal dominant transmission of GLUT1 defi-
ciency syndrome in four families (nine patients). Although this
finding confirms that GLUT1 deficiency syndrome is caused by
de novo mutations of the SLC2A1 gene in the majority of patients,
it emphasizes on the other hand the importance of further clinical
and genetic investigation of family members of GLUT1 deficiency
syndrome patients.
The genotypic and phenotypic variability among patients with
GLUT1 deficiency syndrome is substantial. Our relatively large
series of 57 patients with GLUT1 deficiency syndrome allowed,
for the first time, an analysis of genotype–phenotype correlations.
It has previously been speculated that large-scale deletions, non-
sense, frame shift and splice-site mutations result in 50% loss of
the GLUT1 protein and are associated with the moderate, classical
phenotype of GLUT1 deficiency syndrome. Heterozygous missense
mutations with 50–75% residual function are thought to be asso-
ciated with mild phenotypes. Missense mutations that result in
more than 75% residual transport capacity are speculated to be
associated with a minimal phenotype with symptoms related to
environmental factors, such as fasting or the use of caffeine
(Wang et al., 2005). To allow comparison of the effect of different
types of mutation on the phenotype, we have clustered mutations
that are likely to give a large disruption of glucose transport into
brain (nonsense, frame shift, splice site and translation initiation
mutations (‘type B mutations’) and multiple exon deletions
(‘type C mutations’), and compared them with missense mutations
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(‘type A mutations’; Table 2–4). Our data confirm that type of
mutation is related to the phenotype. Movement disorders were
more frequently seen in patients with type B or C mutations, than
in patients with type A mutations. Furthermore, type of mutation
was related to the severity of mental retardation. Mild retardation
was found more often in patients with type A than in patients
with type B or C mutations. However, severe mental retardation
was found in a few patients with type A mutations and, in con-
trast, a mild retardation in some patients with a type B or C muta-
tions. Additionally, patients with the same mutation displayed a
heterogeneous range of type and severity of phenotype. Even
within families with autosomal dominant transmission of GLUT1
deficiency syndrome, phenotypic diversity was significant, which
suggests that secondary genes and other proteins may be involved
in glucose transport. Another explanation for the phenotypic
diversity is a modulating effect of DNA variants regulatory ele-
ments of the wild-type GLUT1 allele that may modulate the
expression level of the GLUT1 transporter. This phenotypic diver-
sity within families with autosomal transmission of GLUT1 defi-
ciency syndrome has important implications for genetic
counselling. It should be emphasized that although a patient has
very few symptoms it is possible that a future child with the same
mutation will be severely affected. On the other hand, the argu-
ment may be reversed in case of a more severely affected patient.
For the first time, genotype could be correlated with CSF
parameters (Fig. 2A–C). Patients with type B or C mutations had
lower CSF : blood glucose ratios and lower CSF glucose than
patients with type A mutations. This suggests that the residual
GLUT1 activity in the blood–brain barrier correlates with the
CSF : blood glucose ratio as well as the CSF glucose. In addition,
the CSF : blood glucose ratio was correlated with phenotype (Fig.
2D–F). The early-onset classical phenotype was correlated with
lower CSF : blood glucose ratios than the late-onset classical phe-
notype and the non-classical phenotype. This suggests that the
degree of disruption of glucose transport into the brain is an indi-
cator of the type and severity of clinical symptoms in GLUT1 defi-
ciency syndrome. In the individual patient, however, a very low
CSF : blood glucose ratio was not always related to a more severe
phenotype. Apparently, the CSF : blood glucose ratio does not
(solely) reflect the severity of the symptoms in GLUT1 deficiency
syndrome. A possible explanation for a very low CSF : blood glu-
cose ratio in patients with a relatively mild phenotype is the order
in which the lumbar and vein puncture have been performed. If
blood samples are taken after the lumbar puncture is performed,
the blood glucose can be raised due to stress and this will lower
the calculated CSF : blood glucose ratio. Furthermore, CSF and
blood glucose can fluctuate in the individual patient due to fasting
and stress.
In conclusion, GLUT1 deficiency syndrome is a treatable disor-
der of glucose transport into the brain caused by a variety of
mutations in the SLC2A1 gene, which lead to a neurological dis-
order with large phenotypic diversity, including a substantial
number of patients without epilepsy. A lumbar puncture should
be performed in every patient suspected of GLUT1 deficiency syn-
drome, as the simple measurement of CSF glucose is an inexpen-
sive, widely available method to rapidly provide a sensitive marker
for selecting patients for mutation analysis of the SLC2A1 gene
and early introduction of the ketogenic diet.
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